Madalina Tuluc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Madalina Tuluc has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Adam J. Luginbuhl
Department of Otolaryngology–Head and Neck Surgery Thomas Jefferson University Philadelphia Pennsylvania USA
44 shared publications - Athanassios Argiris
Department of Medical Oncology—Head and Neck Surgery, Sidney Kimmel Medical College, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
44 shared publications - David M. Cognetti
Department of Otolaryngology–Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania
44 shared publications - Jennifer Maria Johnson
Department of Otolaryngology–Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania
44 shared publications - Joseph M. Curry
Department of Otolaryngology–Head and Neck Surgery Thomas Jefferson University Hospital Philadelphia Pennsylvania USA
44 shared publications - Larry Harshyne
Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, USA
44 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Representativeness of Study Participants
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Representativeness of Study Participants
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Baseline heatmap profiling of pre-treatment peripheral blood samples
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Baseline heatmap profiling of pre-treatment peripheral blood samples
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Association of pre-treatment primary size and degree of pathologic response
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Association of pre-treatment primary size and degree of pathologic response
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Association of PD-L1 classification with pathologic response
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Association of PD-L1 classification with pathologic response
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Three-year estimate of overall survival and recurrence-free survival from time of surgery
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Three-year estimate of overall survival and recurrence-free survival from time of surgery
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Supplemental table 2: Associated demographic and clinical data by patient
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Supplemental table 2: Associated demographic and clinical data by patient
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Raw Values of Cytokine titers from baseline to post-treatment
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Raw Values of Cytokine titers from baseline to post-treatment
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Association of primary radiographic response with pathological response
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Association of primary radiographic response with pathological response
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Population Analysis and Immunologic Landscape of Melanoma in People Living with HIV
Figure S3. Schematic representation of patient samples, assays, and analysis workflow. The diagram indicates the major steps involved in tissue processing, spatial transcriptomic assay and analysis, and multiplex immunofluorescence assay and analysis. Created in BioRender. Romano, G (2025). https://BioRender.com/kb979ps .
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Population Analysis and Immunologic Landscape of Melanoma in People Living with HIV
Figure S3. Schematic representation of patient samples, assays, and analysis workflow. The diagram indicates the major steps involved in tissue processing, spatial transcriptomic assay and analysis, and multiplex immunofluorescence assay and analysis. Created in BioRender. Romano, G (2025). https://BioRender.com/kb979ps .